1. The presence of proteinuria is not essential to the diagnosis of pre-eclampsia under many diagnostic consensus statements. The aim of the present study was to assess maternal and perinatal outcomes after proteinuric pre-eclampsia compared with other non-proteinuric disease presentations. 2. An individual patient data review (n = 670) was undertaken for 2003-2006 at a tertiary referral centre in Sydney (NSW, Australia). Women were diagnosed in accordance with the Australasian Society for the Study of Hypertension in Pregnancy Consensus Statement. Data were analysed with the Chi-squared test, t-tests and non-parametric tests. Statistical significance was set at P < 0.05. 3. The proteinuric cohort had higher systolic and diastolic blood pressure recordings than the non-proteinuric cohort (160/102 and 149/94 mmHg, respectively; P < 0.001), and were also administered magnesium sulphate more frequently (44 vs 22%, respectively; P < 0.001), delivered at earlier gestation (37 vs 38 weeks, respectively; P < 0.001), required operative delivery more frequently (63 vs 48%, respectively; P < 0.001) and received more antihypertensive medications during the antenatal period (72 vs 57%, respectively; P < 0.001). Acute renal failure and acute pulmonary oedema were rare. Four cases of eclampsia all occurred in non-proteinuric women. The perinatal mortality rate was lower for the offspring of women with proteinuric pre-eclampsia compared with offspring of non-proteinuric women (13/1000 and 31/1000, respectively; P = 0.006). 4. The results of the present study indicate that the presence of proteinuria denotes a group of women who have higher antenatal blood pressure, who deliver at earlier gestation and require operative delivery more commonly, although it is not an indicator of other markers of maternal morbidity or perinatal mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1440-1681.2009.05334.xDOI Listing

Publication Analysis

Top Keywords

presence proteinuria
8
proteinuric pre-eclampsia
8
pre-eclampsia compared
8
blood pressure
8
earlier gestation
8
operative delivery
8
non-proteinuric women
8
perinatal mortality
8
women
6
0001
5

Similar Publications

Approach to investigation and management of proteinuria in pregnancy.

Clin Med (Lond)

December 2024

Women's Centre, John Radcliffe Hospital, Oxford University Hospitals, Headley Way, Headington, OX3 9DU. Electronic address:

Pregnancy leads to significant changes in renal physiology which results in increased in glomerular filtration rate (GFR) and enhanced protein excretion. These changes may continue in the postnatal period and might be observed for five to six months after birth. Once confirmed, proteinuria warrants investigation and close surveillance.

View Article and Find Full Text PDF

Background: Primary immunoglobulin (Ig)-associated mesangiocapillary glomerulonephritis (Ig-MCGN) is an immune complex glomerulonephritis of unknown etiology. It is a common cause of chronic kidney disease in developing countries. There is limited data available on renal and patient outcomes of this disease from developing countries.

View Article and Find Full Text PDF

Introduction: There exists a prevailing concern regarding the heightened susceptibility of women with a solitary kidney to unfavorable consequences during pregnancy. Irrespective of the underlying etiology, individuals with a solitary kidney are advised to have regular annual screenings for blood pressure and urinalysis due to their increased susceptibility to developing proteinuria, hypertension, and renal failure.

Objective: To investigate the risk of adverse pregnancy outcomes in women with a maternal solitary kidney by comparing maternal and fetal outcomes to those of healthy pregnant women.

View Article and Find Full Text PDF

Background: Lupus nephritis (LN) is a major complication of systemic lupus erythematosus. Like other types of glomerulonephritis, podocyte injury has been observed in patients with LN. However, the association between podocyte injury and kidney prognosis in patients with LN has not been well elucidated.

View Article and Find Full Text PDF

Positivity of antiphosphatidylserine/prothrombin antibodies identifies a subgroup of more severe antiphospholipid syndrome patients.

Clin Exp Rheumatol

December 2024

Laboratoire d'Immunologie, AP-HP, Hôpital Européen Georges Pompidou, Paris; and Inflammation, Complement, and Cancer, Université Paris Cité, INSERM, UMRS 1138, Cordeliers Research Center, Team Paris, France.

Objectives: Antiphospholipid syndrome (APS) is an autoimmune disease combining the occurrence of thrombotic and/or obstetric events with the persistent presence of antiphospholipid antibodies (i.e. lupus anticoagulant (LA), anti-cardiolipin (aCL) and anti-beta-2-glycoprotein I (aβ2GPI) antibodies).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!